medRxiv preprint doi: https://doi.org/10.1101/2022.05.03.22274641; this version posted May 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

1	
2	
3	
	Correlation of Sugnasted COVID 10 Sumptoms with COVID 10
4 5	Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children
6 7	Sanika A. Satoskar ⁴ , MPH, Daniel Hindman ^{1,2*} , MD, MPH, Amyna Husain ¹ , DO, Laura Prichett ³ , PhD, MHS, Oluwakemi B. Badaki ¹ , MD, PhD, Ann Kane ^{1*} , MD
8 9	¹ Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA
9 10 11	² Department of Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
11 12 13 14	³ Biostatistics, Epidemiology, and Data Management (BEAD) Core, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA
14 15 16	⁴ Northeast Ohio Medical University, Rootstown, OH, USA
17 18 19 20 21	* Correspondence: Ann Kane annkane@jhu.edu Daniel Hindman dhindma1@jhu.edu
22	Keywords: COVID-19, Pediatrics, Emergency Medicine, Infectious Diseases, Epidemiology
23 24	Word Count: 2,053 Number of tables: 2
25	
26	
27	
28	
29	
30	
31	
32	

33 Abstract

34 <u>Background:</u> Early in the pandemic, COVID-19 was found to infect adults at higher rates than

35 children, leaving limited data on disease presentation in children. Further understanding of the

36 epidemiology of COVID-19 symptoms among children is needed. Our aim was to explore how

37 symptoms vary between children testing positive for COVID-19 infection versus children testing

38 negative.

39 <u>Methods:</u> Data analysis of symptom prevalence among pediatric patients presenting to emergency

40 departments (ED) in the Johns Hopkins Health System (JHHS) with concern for COVID-19 who

subsequently received COVID-19 testing. Inclusion criteria included patients 0-17 years-of-age, ED
 evaluation between March 15th, 2020 - May 11th, 2020, and those who were ordered for COVID-19

42 testing. Chart review was performed to document symptoms using ED provider notes. Comparisons

- 44 were made using chi-squared t-tests and Student's t-tests.
- 45 <u>Results:</u> Fever (62.6%) and cough (47.9%) were the most prevalent symptoms among children with
- 46 suspected COVID-19 infection. Compared to children with a negative COVID-19 test, children who

47 tested positive had higher prevalence of myalgia (21.7% vs 6.0%) and loss of taste/smell (15.2% vs

48 0.9%). Over half of the children who tested positive for COVID-19 had public insurance (52.2%) and

49 58.7% of the positive tests occurred among children with Hispanic ethnicity.

50 <u>Conclusions:</u> Myalgia and loss of taste/smell were found to be significantly more prevalent among

51 COVID-19 positive children compared to children testing negative. Additionally, children with

52 public insurance and those with Hispanic ethnicity were more likely to test positive, emphasizing the

53 importance of social factors in the screening and decision-making process.

- 54
- 55
- 56
- 57
- ~ 1
- 58
- 59
- -
- 60
- 61
- 62
- 63
- 64
- 65
- 66

67 **1** Introduction

68 COVID-19 has had widespread effects across the United States (US), including over

70,000,000 cases diagnosed and over 850,000 deaths since the start of the pandemic, as of January
 26, 2022 [1]. Early in the pandemic, SARS-CoV-2 was found to infect adults at a much higher rate

with more severe manifestations compared to children (0-17 years old) [2-4]. As a result, initial

research efforts to understand COVID-19 were focused largely on the adult population, leaving very

73 limited data on disease epidemiology among children.

Recent data shows that COVID-19 infection may present differently in children compared to adults, as seen by differences in the timing of symptom presentation and disease severity [3-6]. It is, therefore, plausible that the prevalence of certain symptoms will vary in the pediatric population compared to adults. Further understanding of the epidemiology of symptoms among children is

78 necessary for guiding decisions regarding testing.

Although many children have asymptomatic infections [6], studies show that children with symptomatic SARS-CoV-2 infections develop symptoms that range in severity across multiple organ systems. These symptoms have been shown to primarily affect the respiratory system, and include cough, sore throat, and shortness of breath [7]. Gastrointestinal (GI) symptoms are also common and include diarrhea and vomiting. Recent evidence shows that the Multisystem Inflammatory Syndrome (MIS-C), a serious condition resulting in systemic inflammation that adversely affects the heart [8],

85 lungs, kidneys and GI organs, is also associated with COVID-19 in children [9-11].

However, an analysis to further explore the association between individual symptoms with COVID-19 test positivity has not been performed in children. Assessing whether certain symptoms are more specific for a positive COVID-19 test has utility to the clinical provider, providing a gauge that helps to discern whether any particular symptom is likely to place a patient in one of two groups: COVID-19 illness or not COVID-19 illness. This is crucial as it can help aid in risk stratification and efficient utilization of testing resources in children, which is critical to pandemic control [12-13]

92 especially when resources are scarce, as was evident during the early months of the pandemic.

Given the varying presentations of pediatric COVID-19 illness, we conducted an analysis of symptom prevalence among pediatric patients presenting to emergency departments with concern for COVID-19 who subsequently received COVID-19 testing. We collected data from three pediatric emergency department (ED) facilities in a single health system during the initial stages of the pandemic. Our primary specific aim was to explore how symptoms vary between children testing positive for COVID-19 infection versus children testing negative, which was used to associate individual symptoms to COVID-19 test positivity.

100 2 Methods

101 **2.1 Design and Sample:**

We performed a retrospective secondary data analysis of children from 0 through 17 years of age who presented with possible COVID-19 disease to three Pediatric ED facilities in a single health system – two suburban community-based hospitals (PED 2, PED 3) and an urban designated level 1 pediatric trauma center (PED 1). Relevant encounters took place between March 15th, 2020 and May 11th, 2020. We included any patient who was ordered for COVID-19 testing during the time period. COVID-19 testing was ordered based on if the patient met the testing algorithm criteria set at the

- 108 time, and this algorithm changed over the study period as the pandemic evolved. SARS-CoV-2
- 109 testing was performed using a PCR assay. Molecular assays used for diagnosis at the time included
- 110 Xpert Xpress SARS-CoV-2/Flu/RSV (Cepheid), NeuMoDx SARS-CoV-2 (Qiagen), Cobas SARS-
- 111 CoV-2 (Roche), ePlex Respiratory Pathogen Panel 2 (Roche), Aptima SARS-CoV-2 (Hologic),
- 112 Accula SARS-CoV-2 assays (ThermoFisher Scientific), and RealStar® SARS-CoV-2 RT-PCR
- 113 (Altona Diagnostics) [14-17]. Choice of test method was based on what was optimal for fastest result
- turnaround time given the staffing during the shift and test volumes. ED visits that were transfers
- 115 from one of the other two facilities were excluded. This study was approved by the Johns Hopkins
- 116 University Institutional Review Board (IRB00246826).

117 **2.2 Data Source:**

We utilized data collected via a Precision Medicine Analytics Data Commons Platform
 (PMAP) based on electronic medical records (EMR) [18]. Relevant variables included the date of the

120 visit, the associated pediatric emergency department, vital signs, and patient demographics, including

age, sex, race, ethnicity, and insurance. We also included receipt of SARS-CoV-2 testing, results of

122 SARS-CoV-2 testing, isolation orders, acuity measured with the emergency severity index (ESI),

- 123 presence of influenza-like illness (ILI) symptoms, and the patient's area deprivation index (ADI)
- 124 based on the census block.

For every encounter where SARS-CoV-2 testing was obtained, we performed chart review 125 126 based on a pre-determined protocol to document the presence or absence of symptoms using provider 127 notes in the ED. Pertinent symptoms included fever, headache, sore throat, cough, shortness of 128 breath, myalgias, diarrhea, and loss of taste or smell. We used REDCap for data entry. All charts that 129 were flagged for questions were reviewed by a single senior investigator to resolve any ambiguity. 130 Missing data were not imputed, however there were very little missing data. Out of the total 516 131 patients, 18 patients had missing data for some of the variables and these patients were excluded from 132 the analysis involving those variables.

133 2.3 Data Analysis:

134 We analyzed data using Microsoft Excel for Mac 2021 and StataIC 16.1 (StataCorp. 2019. 135 Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC). The prevalence of each 136 pertinent symptom was found by dividing the number of children presenting to the ED with that 137 symptom over the total ED visits in our cohort during that time period. The prevalence rate of each 138 symptom was then compared between children who tested positive for SARS-CoV-2 to those who 139 tested negative for SARS-CoV-2. Subjective parameters including myalgias, headaches, and loss of 140 taste or smell were analyzed by a subgroup analysis which included only children above 5 years-of-141 age. We made comparisons using chi-squared t-tests for categorical variables and Student's t tests for 142 continuous variables.

143 **3 Results**

We identified 516 patient encounters where providers were concerned for possible COVID-19
and subsequently tested for SARS-CoV-2. There were 46 (8.9%) children who tested positive for

146 SARS-CoV-2 and 470 (91.1%) who tested negative. Table 1 presents summary descriptive

147 characteristics of the study population.

The majority of COVID-19 cases occurred in the 12-17 years age group (47.8%). The mean age among those who tested positive was 8.76 years compared to 6.64 years among those who were negative (p = 0.01). Although the majority of our study population consisted of non-Hispanics (78.5%), 58.7% of positive tests occurred among children with Hispanic ethnicity. The majority of children who tested negative for SARS-CoV-2 were either non-Hispanic Black (35.1%) or non-Hispanic White (30.4%). Over half of the children who tested positive for SARS-CoV-2 had public health insurance (52.2%).

Fever (62.6%) and cough (47.9%) were the most prevalent symptoms among children suspected of SARS-CoV-2. When compared to children with a negative SARS-CoV-2 test, children who tested positive had a significantly higher prevalence of myalgia (21.7% vs 6.0%, p-value = 0.001) and loss of taste or smell (15.2% vs 0.9%, p-value < 0.001), as summarized in **Table 2**. There were no significant differences in the prevalence of sore throat, cough, shortness of breath, and

160 diarrhea symptoms between children testing positive versus negative for SARS-CoV-2.

161 **4 Discussion**

In this retrospective secondary data analysis utilizing EMR data and chart review, we found that among children who present with suspected COVID-19 infection, fever and cough are the most prevalent symptoms. However, we find that symptoms of myalgia and loss of taste or smell are associated with COVID-19 positivity in our pediatric patient population.

166 Although many studies have documented a variety of symptoms, including these [6-7], fever 167 and cough have been reported as two predominant symptoms associated with SARS-CoV-2 infection in children [7-8]. Fever and cough were also found to be present in the majority of children who 168 169 underwent testing for COVID-19 infection in our study. However, interestingly, it was myalgia and 170 loss of taste or smell that were significantly associated with a positive COVID-19 test result. Myalgia 171 symptoms have been implicated in many inflammatory conditions [9]. It may be possible that in 172 children suspected of COVID-19 infection, myalgia may be a direct manifestation of the systemic 173 inflammatory state implicated in COVID-19 pathogenesis, and therefore a more specific indicator for 174 positive COVID-19 infection compared to other viral respiratory symptoms alone.

Our study took place during the early months of the pandemic, when testing resources were scarce and limited, and as a result resource allocation and utilization had to be done prudently. Currently, COVID-19 infection rates are increasing in the pediatric population [19-20], and several health systems are starting to face similar testing resource shortages as was evident early in the pandemic [21]. Our study identifies symptoms that are most specific for SARS-CoV-2 positivity in our pediatric study population, which is essential to aid in strengthening COVID-19 test specificity to aid in efficient resource utilization.

In our study population, racial and socioeconomic factors had a strong association with 182 183 SARS-CoV-2 positivity. Children who had public insurance or no insurance were significantly more 184 likely to test positive for SARS-CoV-2 compared to children with private insurance. Additionally, we 185 found ethnicity to be significantly associated with SARS-CoV-2 positivity where Hispanic children 186 had a higher likelihood of testing positive compared to non-Hispanic children. Although this 187 phenomenon has been documented in adults, our study provides further insight among the pediatric 188 population. This is especially crucial since the urban hospitals under the Johns Hopkins Health 189 System (JHHS) predominantly serve Black and Hispanic populations, mainly from within and 190 surrounding the Baltimore area. Interestingly in our study, most of our study population consisted of

191 non-Hispanic children, however over half of the positive tests occurred in Hispanic children. It has

192 been extensively documented that many children belonging to minority racial and ethnic groups 193 reside in poorer neighborhoods with significantly lower resources [22-24]. These children often live

194 in high-density overcrowded housing, are more reliant on public transportation, and lack preventive

195 health services, all of which may impact their ability to adhere to social distancing guidelines and

196 subsequently increase their susceptibility to COVID-19 exposure [25-26]. Although the increased

197 COVID-19 positivity rates that were observed in Hispanics and in patients with public or no

198 insurance in our study could be in part due to the sociodemographic structure of the surrounding

199 areas, several studies have shown that minority racial groups and those belonging to lower

200 socioeconomic statures were at increased risk for serious and fatal COVID-19 infections throughout

201 the pandemic [27]. Our findings corroborate with this and highlight the importance of incorporating

202 racial and social factors in screening for COVID-19 infection.

203 Our study has several limitations. First, our data contained sampling and ascertainment bias 204 since SARS-CoV-2 testing was based on symptom presentation. We did not test children at random. 205 rather we tested children based on the presence of certain symptoms, which were pre-determined by 206 our testing algorithms at that time. Initially, these symptoms included only fever and respiratory 207 symptoms. Diarrhea and loss of taste/smell were added late in the study period, which likely explains 208 the observed lower prevalence of those symptoms in our study population. Second, we assessed 209 patient encounters that occurred during the early months of the pandemic. Data on COVID-19 210 symptoms were just beginning to emerge at that time, which may have played a role in symptom 211 documentation and triage. Third, our study was limited to hospitals that are situated in urban settings 212 in a single state, which limits generalizability. Finally, we were not able to assess social and 213 environmental factors such as household structure, parental occupation, and environmental

214 exposures, all of which may influence disease severity and subsequent symptom presentation.

215 As evidence continues to grow, our study provides further insight into COVID-19 symptoms 216 among the pediatric population. However, the presence or absence of any single symptom, other than 217 possibly the sudden loss of taste or smell, is not sufficient to guide clinical decision-making in testing 218 for SARS-CoV-2 among pediatric patients presenting to emergency facilities. When considering 219 testing for COVID-19, clinicians should be attuned to other factors that may predispose patients to 220 increased risk, such as social determinants of health and patients' social habits. Additionally, given 221 that COVID-19 infectivity is growing in the pediatric population with the addition of newer variants 222 as compared to the start of the pandemic, it is essential that clinicians maintain a low threshold for 223 testing children with a variety of symptoms, allowing for improved disease detection and aiding the 224 prevention of subsequent spread.

- 225
- 226
- 227
- 228
- 229
- 230
- 231

232 **5 Tables**

Table 1. Patient Characteristics of those tested for COVID-19. *Note.* NH = non-Hispanic, ADI = area deprivation index. The ^ap-value is a comparison of patient characteristics between children who tested positive versus children who tested negative for COVID-19. For continuous variables, means are compared with *t* tests. For categorical variables, proportions are compared with chi-square tests

are compared with *t* tests. For categorical variables, proportions are compared with chi-square te

Characteristics	Tested (n = 516)	Positive $(n = 46)$	Negative (n = 470)	^a p-valu
Total	516 (100.0%)	46 (8.9%)	470 (91.1%)	< 0.001
Age (SD)	6.64 (5.84)	8.76 (6.38)	6.43 (5.75)	0.01
Age category				
0-13 months	137 (26.6%)	10 (21.7%)	127 (27.0%)	0.008
13 mos-4 years	129 (25.0%)	5 (10.9%)	124 (26.4%)	
5-11 years	107 (20.7%)	9 (19.6%)	98 (20.9%)	
12-17 years	143 (27.7%)	22 (47.8%)	121 (25.7%)	
Female sex	262 (50.8%)	25 (54.4%)	237 (50.4%)	0.61
Race/Ethnicity				
NH White	149 (28.9%)	6 (13.0%)	143 (30.4%)	<.0001
NH Black	171 (33.1%)	6 (13.0%)	165 (35.1%)	
Hispanic	111 (21.5%)	27 (58.7%)	84 (17.9%)	
Asian	45 (8.7%)	3 (6.5%)	42 (8.9%)	
Other/Unknown	40 (7.8%)	4 (8.7%)	36 (7.7%)	
Insurance				
Public	261 (50.6%)	24 (52.2%)	237 (50.4%)	< 0.001
Private	208 (40.3%)	7 (15.2%)	201 (42.8%)	
Other	24 (4.7%)	8 (17.3%)	16 (3.4%)	
Uninsured	23 (4.5%)	7 (15.2%)	16 (3.4%)	
Mean ADI	5.13 (2.82)	5.65 (2.86)	5.08 (2.82)	0.19

237

238

239

240

241

- 242 **Table 2.** Symptom Complaints of those tested for COVID-19. The ^ap-value is a comparison of
- symptoms between children who tested positive versus children who tested negative for COVID-19.
- 244 For categorical variables, proportions are compared with chi-square tests

Symptoms	Positive COVID test	Negative COVID test	^a p-value
	(n=46)	(n= 470)	
History of Fever	36 (78.3%)	287 (61.1%)	0.05
Headache	11 (23.9%)	56 (11.9%)	0.06
Sore throat	8 (17.4%)	50 (10.6%)	0.30
Cough	24 (52.2%)	223 (47.4%)	0.44
Shortness of Breath	9 (19.6%)	76 (16.2%)	0.70
Myalgia	10 (21.7%)	28 (6.0%)	0.001
Diarrhea	2 (4.3%)	56 (11.9%)	0.25
Loss of taste or smell	7 (15.2%)	4 (0.9%)	< 0.001

245

246 6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest.

249 **7** Author Contributions

- SS conceptualized and designed the study, analyzed, and interpreted the data, drafted the manuscript,and critically revised the manuscript for intellectual content.
- 252 DH, AH, LP, OB, and AK conceptualized and designed the study, acquired, analyzed, and interpreted 253 the data, critically revised the manuscript for intellectual content, provided administrative, technical,
- and material support for the study, and provided overall study supervision.
- 255 All authors read and approved the final manuscript.

256 8 Funding

257 This project was funded by the Emergency Medicine Foundation COVID-19 Research Grant

258 9 References

- World Health Organization. WHO Coronavirus (COVID-19) Dashboard (2021).
 https://covid19.who.int. Accessed October 24, 2021.
- Centers for Disease Control and Prevention. Information for Pediatric Healthcare Providers (2020). <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html</u>. Accessed October 24, 2021.
- Girona-Alarcon M, Bobillo-Perez S, Sole-Ribalta A, Hernandez L, Guitart C, Suarez R, et.al.
 The different manifestations of COVID-19 in adults and children: a cohort study in an intensive care unit. *BMC Infect Dis*. 2021; 21,87. doi: 10.1186/s12879-021-05786-5

267	4.	Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children
268	_	Fare Better than Adults. Indian J Pediatr. 2020; 1-10. doi: 10.1007/s12098-020-03322-y
269	5.	Healthline. How COVID-19 Affects Children Compared to Adults (2020).
270		https://www.healthline.com/health-news/how-covid-19-affects-children-compared-to-adults.
271		Accessed October 24, 2021.
272	6.	Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et.al. Clinical characteristics of COVID-19 in
273		children compared with adults in Shandong Province, China. Infection. 2020; 1-8. doi:
274		10.1007/s15010-020-01427-2
275	7.	DeBiasis RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et.al. Severe Coronavirus
276		Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. J
277		Pediatr. 2020; 223:199-203. doi: 10.1016/j.jpeds.2020.05.007
278	8.	Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et.al. Acute Heart
279		Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-
280		CoV-2 Pandemic. Circulation. 2020; 142(5). doi: 10.1161/CIRCULATIONAHA.120.048360
281	9.	Centers for Disease Control and Prevention. For Parents: Multisystem Inflammatory
282		Syndrome in Children (MIS-C) associated with COVID-19 (2021).
283		https://www.cdc.gov/mis/mis-c.html. Accessed October 24, 2021.
284	10.	Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et.al.
285		COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines;
286		a Western New York approach. Prog Pediatr Cardiol. 2020; 101232. doi:
287		10.1016/j.ppedcard.2020.101232
288	11.	Jiang L, Tang, K, Levin M, Irfan O, Morris SK, Wilson K, et.al. COVID-19 and multisystem
289		inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020; 20(11):e276-
290		e288. doi: 10.1016/S1473-3099(20)30651-4
291	12.	Hodgson LE, Leckie T, Hunter A, Prinsloo N, Venn R, Forni L. COVID-19 recognition and
292		digital risk stratification. <i>Future Healthc J.</i> 2020; 7(3):e47-e49. Doi: 10.7861/fhj.2020-0037
293	13.	Ma J, Shi X, Xu W, Ly F, Wu J, Pan Q, et.al. Development and validation of a risk
294		stratification model for screening suspected cases of COVID-119 in China. Aging. 2020;
295		12(14):13882-13894. doi: 10.18632/aging.103694
296	14.	Jarrett J, Uhteg K, Forman MS, Hanlon A, Vargas C, Carroll KC, et.al. Clinical performance
297		of the GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract
298		infections. J Clin Virol. 2021; 135:104737.
299	15.	Mostafa HH, Carroll KC, Hicken R, Berry GJ, Manji R, Smith E, et.al. Multi-center
300	10.	Evaluation of the Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV Test. J Clin Microbiol.
301		2020; doi:10.1128/JCM.02955-20.
302	16	Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. Comparison of the
303	10.	analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated
304		molecular assays. <i>J Clin Virol.</i> 2020; 130:104578
305	17	Uhteg K, Jarrett J, Richards M, Howard C, Morehead E, Geahr M, et.al. Comparing the
306	17.	analytical performance of three SARS-CoV-2 molecular diagnostic assays. <i>J Clin Virol</i> .
307		2020; 127:104384
308	18	Johns Hopkins Institute for Clinical and Translational Research. Precision Medicine
309	10.	Analytics Platform (PMAP). <u>https://ictr.johnshopkins.edu/programs_resources/programs-</u>
310		resources/i2c/pmap/. Accessed October 24, 2021.
310	10	AAP. Children and COVID-19: State-Level Data Report (2022).
312	17.	https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-
312		covid-19-state-level-data-report/. Accessed January 16, 2022.
313	20	Jones, J. Epidemiology of COVID-19 in Children Aged 5-11 years. Epidemiology Task Force
	<i>2</i> 0.	
315		CDC COVID-19 Public Health Response. 2021. Available online at:

316	https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/03-COVID-
317	Jefferson-508.pdf.
318	21. NBC. Hospital are experiencing supply shortages for COVID tests.
319	https://www.nbcrightnow.com/national/some-hospitals-are-experiencing-supply-shortages-
320	for-covid-tests/article_2f24b7de-740e-11ec-b5f3-bfdba6400f2d.html. Accessed January 16,
321	2022
322	22. Lamb MR, Kandula S, Shaman J. Differential COVID-19 case positivity in New York City
323	neighborhoods: Socioeconomic factors and mobility. Influenza Other Respi Viruses. 2021;
324	15:209-217.
325	23. Acevedo-Garcia D, Noelke C, McArdle N, Sofer N, Hardy EF, Weiner M, Baek M, et.al.
326	Racial And Ethnic Inequities In Children's Neighborhoods: Evidence From The New Child
327	Opportunity Index 2.0. Health Aff. 2020; 39(10):1693-1701. doi: 10.1377/hlthaff.2020.00735
328	24. Johns Hopkins Medicine. The Johns Hopkins Hospital Fiscal Year 2017 Community Benefits
329	Report Narrative. https://web.jhu.edu/administration/gca/projects/publications-and-
330	reports/CBR%20Reports/CBR%202017/FY%202017%20JHH%20CBR%20Report.pdf.
331	Accessed November 19, 2021.
332	25. Gershengorn HB, Patel S, Shukla B, Warde PR, Bhatia M, Parekh D, et.al. Association of
333	Race and Ethnicity with COVID-19 Test Positivity and Hospitalization Is Mediated by
334	Socioeconomic Factors. Ann Am Thorac Soc. 2021; 18(8): 1326-1334.
335	26. AAP News. Study: Hispanic, Black, low-income children had highest rates of SARS-CoV-2
336	2020. https://www.aappublications.org/news/2020/08/05/covid19disparities080520. Accessed
337	October 30, 2021.
338	27. Muñoz-Price LS, Nattinger AB, Rivera F, Hanson R, Gmehlin CG, Perez A, Singh S, Buchan
339	BW, Ledeboer NA, Pezzin LE. Racial Disparities in Incidence and Outcomes Among Patients
340	with COVID-19. JAMA Netw Open. 2020;3(9), e2021892.
341	28. Feketea GM, Vlacha V. A Decision-Making Algorithm for Children With Suspected
342	Coronavirus Disease 2019. JAMA Pediatr. 2020; 174(12):1220-1222. Doi:
343	10.1001/jamapediatrics.2020.2999
344	29. Johns Hopkins Medicine. COVID in Babies and Kids: Symptoms and Prevention.
345	https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-in-
346	babies-and-children. Accessed October 24, 2021.
347	30. Teherani MF, Kao CM, Camacho-Gonzalez A, Banskota S, Shane AL, Linam WM, Jaggi P.
348	Burden of Illness in Households With Severe Acute Respiratory Syndrome Coronavirus 2-
349	Infected Children. Journal of Pediatric Infectious Diseases Society. 2020; 9(5),613-616.
350	31. Viner RM, Ward JL, Hudson LD, Ashe M, Patel SV, Hargreaves D, Whittaker E. Systematic
351	review of reviews of symptoms and signs of COVID-19 in children and adolescents. Archives
352	of Disease in Childhood. 2021; 106:802-807.
353	32. Pahwa R, Goyal A, Bansal P, Jialal I. "Chronic Inflammation". In: StatPearls. Treasure
354	Island, FL: StatPearls Publishing LLC. 2019.
355	33. Habibzadeh P, Mofatteh M, Silawi M, Ghavami S, Faghihi MA. Molecular diagnostic assays
356	for COVID-19: an overview. <i>Crit Rev Clin Lab Sci.</i> 2021; Sep;58(6):385-398. doi: 10.1080/10408262.2021.1884640. Earth 2021 Each 17. DMID: 22505207; DMCID:
357	10.1080/10408363.2021.1884640. Epub 2021 Feb 17. PMID: 33595397; PMCID: PMC7208207
358	PMC7898297

359

360

361 **10 Abbreviations**

- 362 US = United States
- 363 ED = emergency department
- 364 COVID-19 = coronavirus disease 2019
- 365 SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
- 366 MIS-C = multisystem inflammatory syndrome in children
- 367 ILI = influenza-like illness
- 368 PMAP = Precision Medicine Analytics Data Commons Platform
- 369 ESI = emergency severity index
- 370 ADI = area deprivation index
- 371 EMR = electronic medical record
- 372 GI = gastrointestinal
- 373 ILI = influenza-like illness

374 11 Data Availability Statement

375 The dataset generated and analyzed for this study can be obtained from the corresponding authors

upon request.